Teriflunomide

Drug Profile

Teriflunomide

Alternative Names: A-77-1726; Aubagio; AVE-1726; HMR-1726; HMR1726D; RS-61980; SU-0020

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Genzyme Corporation; Sanofi; Sanofi Genzyme
  • Class Antirheumatics; Hydroxybutyrates; Nitriles; Small molecules; Toluidines
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 14 Sep 2016 Pooled results from phase III TEMSO and TOWER trials for Multiple sclerosis presented by Sanofi at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 14 Sep 2016 Updated efficacy and adverse events data from the phase III TEMSO extension trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 14 Sep 2016 Safety and efficacy data from the phase III TOPIC extension trial in Multiple sclerosis presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top